Sharekhan's research report on Cadila Healthcare
Q4FY2019 performance below expectation, high interest cost (due to increased debt to fund Heinz India acquisition) dented profitability. We expect Cadila to deliver sales and profit CAGR of modest 11% and 9%, respectively, over FY2019-FY2021. Margins are likely to remain under pressure as the company witnesses competitive pressure in its niche launches. We have revised downwards our earnings estimates by 15% each for FY2020E and FY2021E.
Outlook
We maintain our Hold recommendation on the stock with lowered PT of Rs. 290.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
